The complexities of hormonal influences and risk of Parkinson's disease

Movement Disorders

Volumn 29, Issue 7, 2014, Pages 845-848

  Marras, Connie ^a   Saunders Pullman, Rachel ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TESTOSTERONE;

EDITORIAL; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LIVE BIRTH; MENARCHE; MENOPAUSE; ORAL CONTRACEPTIVE USE; OVARIECTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; REPRODUCTIVE HISTORY; TREATMENT DURATION; FEMALE; HORMONE SUBSTITUTION; PHYSIOLOGY; REPRODUCTION;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; PARKINSON DISEASE; REPRODUCTION;

EID: 84902155098     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25891     Document Type: Editorial

References (33)

1. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157:1015-1022.
2. Group PsS. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
3. Lyons K, Hubble J, Tröster A, Pahwa R, WC K. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998;21:118-121.
4. Post B, Muslimovic D, van Geloven N, et al. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 2011;26:449-456.
5. Savica R, Grossardt B, Bower J, Ahlskog J, Rocca W. Risk factors for Parkinson's disease may differ in men and women: an exploratory study. Hormones and Behavior 2013;63:308-314.
6. Saunders-Pullman R, Stanley K, San Luciano M, et al. Gender differences in the risk of familial parkinsonism: beyond LRRK2? Neurosci Lett 2011;496:125-128.
7. Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinonsim Relat Disord 2010;16:370-375.
8. Saunders-Pullman R, Wang C, Stanley K, Bressman S. Diagnosis and referral delay in women with Parkinson's disease. Gender Med 2011;8:209-217.
9. Rodriguez-Perez A, Valenzuela R, Villar-Cheda B, Guerra M, Labandeira-Garcia J. Dopaminergic neuroprotection of hormonal therapy in young and aged menopausal rats: Role of the brain angiotensin system. Brain 2012;135:124-138.
10. Suzuki S, Brown C, Dela Cruz C, Yang E, Bridwell D, Wise P. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci U S A 2007;104:6013-6018.
11. Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 2008;104:6013-6018.
12. Wang S, Ren P, Li X, Guan Y, Zhang Y. 17β-estradiol protects dopaminergic neurons in organotypic slice of mesencephalon by MAPK-mediated activation of anti-apoptosis gene BCL2. J Mol Neurosci 2011;45:236-245.
13. Bae Y, Hwang J, Kim Y, Koh J. Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J Korean Med Sci 2000;15:327-336.
14. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001;16:830-837.
15. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004;62:2010-2014.
16. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-209.
17. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886-888.
18. Rugbjerg K, Christensen J, Tjonneland A, Olsen JH. Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 2013;19:457-460.
19. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009;24:1359-1365.
20. Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383-390.
21. Manson J, Bassuk S. Hormone therapy and risk of coronary heart disease: why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511-517.
22. Rossouw J, Prentice R, Manson J, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-1477.
23. Maki P. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause 2013;20:695-709.
24. Marder K, Sano M. Estrogen to treat Alzheimer disease: too little, too late. So what's a woman to do? Neurology 2000;54:2035-2037.
25. Resnick S, Henderson V. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002;288:2170-2172.
26. Sherwin B. Estrogen therapy is time of initiation critical for neuroprotection? Nat Rev Endocrinol 2009;5:620-627.
27. Liu R, Baird D, Park Y, et al. Female reproductive factors, menopausal hormone use, and Parkinson's disease. Mov Disord 2014;29:889-896.
28. Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977-984.
29. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003;60:790-795.
30. Bleil M, Gregorich S, McConnell D, Rosen M, Cedars M. Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease? Menopause 2013;20:1139-1146.
31. Fleming L, Levis S, LeBlanc W, et al. Earlier age at menopause, work, and tobacco smoke exposure. Menopause 2008;15:1103-1108.
32. Brenner S. Solvents may act as estrogen blockers in development of Parkinson disease. Ann Neurol 2012;72:477.
33. Saunders-Pullman R, Derby C, Santoro N, et al. Role of endogenous and exogenous hormone exposure on the risk of Parkinson disease: results from the Women's Health Initiative Observational Study. Neurology 2009;S23.